Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
Tyler C ChervoEric P ElkinJoshua R NugentEmily ValiceLaura B AmsdenIsaac J ErgasJulie R MunnekeMonica FloresGina N SaeleeCrystal A HsiaoJeffery M SchapiroCharles P QuesenberryDouglas A CorleyLaurel A HabelLawrence H KushiJacek SkarbinskiPublished in: PloS one (2024)
By April 2022, 93.5% of persons had detectable SARS-CoV-2 spike antibody, predominantly from COVID-19 vaccination. In this highly vaccinated population and over 18 months into the pandemic, SARS-CoV-2 infection without COVID-19 vaccination was a small contributor to overall population-level seroprevalence.